<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 01 Apr 2021 19:19:01 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>2021年3月FDA批准的5款新药</title><link>https://mp.weixin.qq.com/s/4wQS6VNYSPeZA_LhSxsaxw</link><description></description><content:encoded><![CDATA[2021年3月FDA批准的5款新药]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>符合第五批集采条件品种注射用更昔洛韦，普利制药再下一城获意大利批准</title><link>https://mp.weixin.qq.com/s/gAdy55nLVNmW8oxpUVc-wQ</link><description></description><content:encoded><![CDATA[符合第五批集采条件品种注射用更昔洛韦，普利制药再下一城获意大利批准]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>朗来科技IRAK4抑制剂MY004临床试验申请获国家药品监督管理局受理</title><link>https://mp.weixin.qq.com/s/g3JITGpSxjKKhQplOZTxCQ</link><description></description><content:encoded><![CDATA[朗来科技IRAK4抑制剂MY004临床试验申请获国家药品监督管理局受理]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>强生BCMA/CD3双抗申报临床</title><link>https://mp.weixin.qq.com/s/yMgw9vH6-06Iv5Fc441wcw</link><description></description><content:encoded><![CDATA[强生BCMA/CD3双抗申报临床]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>方生和与PICC再度合作，投保在研药物临床试验</title><link>https://mp.weixin.qq.com/s/pi2XwR3JeyP3Jr0fnQU9JA</link><description></description><content:encoded><![CDATA[方生和与PICC再度合作，投保在研药物临床试验]]></content:encoded><pubDate>Thu, 01 Apr 2021 17:22:53 +0800</pubDate></item><item><title>再鼎医药「瑞派替尼」国内获批上市，填补GIST四线治疗空白</title><link>https://mp.weixin.qq.com/s/YPs84lUrB7dco41syBuZtA</link><description></description><content:encoded><![CDATA[再鼎医药「瑞派替尼」国内获批上市，填补GIST四线治疗空白]]></content:encoded><pubDate>Wed, 31 Mar 2021 17:15:24 +0800</pubDate></item><item><title>礼来IL-2R激动剂申报临床</title><link>https://mp.weixin.qq.com/s/bdNYVlgp-2Sz7rT8zniB0Q</link><description></description><content:encoded><![CDATA[礼来IL-2R激动剂申报临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 17:15:24 +0800</pubDate></item><item><title>40个品种！福建带量采购5月7日开标</title><link>https://mp.weixin.qq.com/s/_X4nvwMmvahZI_3mdRHZDw</link><description></description><content:encoded><![CDATA[40个品种！福建带量采购5月7日开标]]></content:encoded><pubDate>Wed, 31 Mar 2021 17:15:24 +0800</pubDate></item><item><title>特瑞普利单抗第3项适应症即将获批！治疗尿路上皮癌</title><link>https://mp.weixin.qq.com/s/gPrPK_LrvGYAHNxatCsSkQ</link><description></description><content:encoded><![CDATA[特瑞普利单抗第3项适应症即将获批！治疗尿路上皮癌]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:44:55 +0800</pubDate></item><item><title>首个FRα ADC获批临床，华东医药3亿美元引进</title><link>https://mp.weixin.qq.com/s/gcNUACA8kyZ2UEUR74UoYQ</link><description></description><content:encoded><![CDATA[首个FRα ADC获批临床，华东医药3亿美元引进]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:44:55 +0800</pubDate></item><item><title>2020年全球药品销售额TOP100</title><link>https://mp.weixin.qq.com/s/y1ZqKn1aSbiRP7UtYYdncA</link><description></description><content:encoded><![CDATA[2020年全球药品销售额TOP100]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:44:55 +0800</pubDate></item><item><title>罗氏「艾美赛珠单抗」新适应症即将获批</title><link>https://mp.weixin.qq.com/s/oISfFiD6TW1RsVVX62hBSw</link><description></description><content:encoded><![CDATA[罗氏「艾美赛珠单抗」新适应症即将获批]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:44:55 +0800</pubDate></item><item><title>复兴医药引进的CXCR4拮抗剂临床申请获受理</title><link>https://mp.weixin.qq.com/s/o-gj6h7uum0FkFpYMmYzjw</link><description></description><content:encoded><![CDATA[复兴医药引进的CXCR4拮抗剂临床申请获受理]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:44:55 +0800</pubDate></item><item><title>Keytruda乳腺癌sBLA申请遭FDA拒绝</title><link>https://mp.weixin.qq.com/s/Ps8GwQX-TOzdwCYLyFMHmA</link><description></description><content:encoded><![CDATA[Keytruda乳腺癌sBLA申请遭FDA拒绝]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:44:55 +0800</pubDate></item><item><title>NSCLC术后辅助治疗！奥希替尼新适应症即将获批</title><link>https://mp.weixin.qq.com/s/6Bis4Mueb-L8zvwPnaOPJw</link><description></description><content:encoded><![CDATA[NSCLC术后辅助治疗！奥希替尼新适应症即将获批]]></content:encoded><pubDate>Mon, 29 Mar 2021 17:55:51 +0800</pubDate></item><item><title>2021年全球CRO公司排名Top10</title><link>https://mp.weixin.qq.com/s/uMpCqGAmjkVTBBliJ9UE8A</link><description></description><content:encoded><![CDATA[2021年全球CRO公司排名Top10]]></content:encoded><pubDate>Mon, 29 Mar 2021 17:55:51 +0800</pubDate></item><item><title>上交所终止天广实科创板IPO</title><link>https://mp.weixin.qq.com/s/TNbYy9aSIqA0TmkoppG1-g</link><description></description><content:encoded><![CDATA[上交所终止天广实科创板IPO]]></content:encoded><pubDate>Mon, 29 Mar 2021 17:55:51 +0800</pubDate></item><item><title>武田「醋酸艾替班特注射液」即将获批上市</title><link>https://mp.weixin.qq.com/s/2rzV1YM1v8PLn71X7Xa6yQ</link><description></description><content:encoded><![CDATA[武田「醋酸艾替班特注射液」即将获批上市]]></content:encoded><pubDate>Mon, 29 Mar 2021 17:55:51 +0800</pubDate></item><item><title>首款靶向BCMA的CAR-T疗法获FDA批准上市</title><link>https://mp.weixin.qq.com/s/19cVJ2wCj4xXDCUWOSZ8Lg</link><description></description><content:encoded><![CDATA[首款靶向BCMA的CAR-T疗法获FDA批准上市]]></content:encoded><pubDate>Sat, 27 Mar 2021 13:54:09 +0800</pubDate></item><item><title>首个DNA HPV 疫苗在国内正式开展 III 期临床</title><link>https://mp.weixin.qq.com/s/MeTvUEnVgfwTLlRyTgD9Iw</link><description></description><content:encoded><![CDATA[首个DNA HPV 疫苗在国内正式开展 III 期临床]]></content:encoded><pubDate>Fri, 26 Mar 2021 18:32:48 +0800</pubDate></item></channel></rss>